Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 14, 2023 (3 years ago)

dilTIAZem 125mg/125mL

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

dilTIAZem 125mg/125mL (1 mg/mL), added to 0.9% sodium chloride, IV Bag, Rx Only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043, NDC: 72196-6055-1

Affected NDC 72196-6055-01

Compare with the code on your package — it is the most precise check available.

Drug: Diltiazem

Recalling firm
Central Admixture Pharmacy Services, Inc.
Origin
AZ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0953-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Diltiazem recalls

See all

Other recalls by Central Admixture Pharmacy Services, Inc.

All 2023 recalls